Lombardi W L, Litwin S E
Cardiology Division, University of Utah, Salt Lake City 84132, USA.
Coron Artery Dis. 1999 Sep;10(6):361-8. doi: 10.1097/00019501-199909000-00003.
Angiotensin-converting enzyme (ACE) inhibitors were introduced in the early 1980s as a novel class of agents to treat hypertension. Since that time, they have been proven to be a powerful tool in the treatment of symptomatic left ventricular systolic dysfunction. In this article we will summarize the results from clinical trials using ACE inhibitors in the treatment of heart failure and after myocardial infarction. We will discuss some of the mechanisms postulated to account for the beneficial effects associated with ACE inhibitor treatment. Finally, we will highlight some recent controversies in the use of ACE inhibitors.
血管紧张素转换酶（ACE）抑制剂于20世纪80年代初作为一类新型抗高血压药物被引入。从那时起，它们已被证明是治疗有症状的左心室收缩功能障碍的有力工具。在本文中，我们将总结使用ACE抑制剂治疗心力衰竭和心肌梗死后的临床试验结果。我们将讨论一些据推测可解释ACE抑制剂治疗相关有益作用的机制。最后，我们将重点介绍ACE抑制剂使用方面最近的一些争议。
